Literature DB >> 959756

Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment.

C E Mogensen.   

Abstract

The rate of progression of nephropathy was studied in 6 young male diabetics with intermittent proteinuria (Albustix) and in 10 young male diabetics with constant proteinuria by measuring glomerular filtration rate (GFR), renal plasma flow (RPF), and urinary albumin excretion by exact techniques. Albumin excretion was elevated in both the recumbent and the erect position in patients with intermittent proteinuria. GFR and RPF were at the same level as in diabetics without proteinuria, and no deterioration in renal function was noted during a mean control period of 32 months. In the patients with constant proteinuria the fall rate during a mean period of 33.6 months for GFR and RPF was 0.91 ml/min/month +/- 0.68 (S.D.) and 4.38 ml/min/month +/- 3.23 (S.D.) respectively. Initial fall rate in GFR correlated well with long-term fall rate, both of which were studied in 7 patients. In the same patients there was a positive correlation between the fall rate in GFR and diastolic blood pressure as well as albumin clearance. In 8 patients with constant proteinuria and mean blood pressure of 159/101 mmHg, antihypertensive treatment was started with propranolol alone or combined with hydralazine and furosemide. During a treatment period of 47 days blood pressure was reduced to 143/93 mmHg, and in the same period urinary albumin excretion was reduced significantly from a mean value of 3547 mug/min to 2414 mug/min (P less than 0.01). Further control studies will clarify whether end-stage of renal insufficiency will be postponed by antihypertensive treatment.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 959756     DOI: 10.1080/00365517609055274

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  64 in total

1.  The care of patients with chronic kidney disease.

Authors:  Annamaria T Kausz; Andrew S Levey
Journal:  J Gen Intern Med       Date:  2002-08       Impact factor: 5.128

Review 2.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 3.  Mechanisms of diabetic renal and cardiovascular disease.

Authors:  G C Viberti
Journal:  Acta Diabetol Lat       Date:  1990 Jul-Sep

Review 4.  Blood pressure control--effects on diabetic nephropathy progression: how low does blood pressure have to be?

Authors:  Christopher A Newton; Philip Raskin
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

Review 5.  Treatment of hypertension in diabetic patients with nephropathy.

Authors:  R Komers; S Anderson
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

6.  Are the 'second generation' oral hypoglycemic agents really different?

Authors:  E F Pfeiffer
Journal:  Acta Diabetol Lat       Date:  1984 Jan-Mar

7.  Silent diabetic nephropathy.

Authors:  Katia López-Revuelta; Patricia Peña Galdo; Ramona Stanescu; Leticia Parejo; Carmen Guerrero; Elia Pérez-Fernández
Journal:  World J Nephrol       Date:  2014-02-06

Review 8.  Hypertension management in patients with diabetic nephropathy.

Authors:  Anthony L McCall
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

9.  Functional genetic variation in aminopeptidase A (ENPEP): lack of clear association with focal and segmental glomerulosclerosis (FSGS).

Authors:  Stephen Tonna; Savita V Dandapani; Andrea Uscinski; Gerald B Appel; Johannes S Schlöndorff; Kang Zhang; Bradley M Denker; Martin R Pollak
Journal:  Gene       Date:  2007-12-03       Impact factor: 3.688

10.  Blood pressure and metabolic control as risk factors for nephropathy in type 1 (insulin-dependent) diabetes.

Authors:  C Hasslacher; W Stech; P Wahl; E Ritz
Journal:  Diabetologia       Date:  1985-01       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.